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Introduction
Niacin (nicotinic acid), an agent with favourable
effects on lipids, has been shown in clinical trials to
reduce cardiovascular events or atherosclerosis pro-
gression in patients with cardiovascular disease and
dyslipidaemia (1). The use of niacin in clinical prac-
tice has been hampered by poor tolerability, primar-
ily because of ﬂushing, which occurs to some degree
in nearly all patients receiving niacin therapy (2–5).
Although extended-release (ER) formulations of nia-
cin reduce ﬂushing symptoms relative to immediate-
release formulations (6), the occurrence of ﬂushing
remains, requiring initiation at a low dose (i.e.
500 mg per day in the USA) with incremental
increases to a therapeutically effective dose (2 g per
day) after a period of months. Despite gradual titra-
tion, failure to achieve an optimal ER niacin dose
and discontinuation of therapy frequently occur.
Indeed, observational data show higher rates of dis-
continuation with ER niacin in clinical practice than
those reported in clinical trials (7–9), signalling the
need for improved formulations whose development
would be enhanced by objective measures of ER nia-
cin-induced ﬂushing.
The Flushing Symptom Questionnaire
ª (FSQ) is a
quantitative tool to assess aspects of the severity, fre-
quency, duration and bother of ﬂushing (including
symptoms of skin redness, warmth, tingling and⁄or
itching separately and in aggregate). The FSQ was
developed with input from clinical experts and
through interviews with patients who had experi-
enced ﬂushing with current ER niacin-based prod-
ucts. It was pilot tested in patients for content and
comprehension and validated using the data from
this study, described elsewhere (10). The purpose of
the present study was to evaluate the utility of the
FSQ to characterise the severity of patient-reported
ER niacin-induced ﬂushing symptoms during initia-
tion of ER niacin therapy and with persistent use.
SUMMARY
Introduction: Niacin is underutilised because of ﬂushing. Lack of a quantitative
tool to assess niacin-induced ﬂushing has precluded the objective evaluation of
ﬂushing associated with extended-release (ER) niacin formulations. We developed
the Flushing Symptom Questionnaire
ª (FSQ), a quantitative tool to assess patient-
reported ﬂushing, and assessed its ability to characterise ER niacin-induced ﬂush-
ing. Methods: This study focused on the responses to one question in the FSQ,
the Global Flushing Severity Score (GFSS), reported on a 0–10 scale (none = 0,
mild = 1–3, moderate = 4–6, severe = 7–9 and extreme = 10) to assess ﬂushing
during ER niacin initiation (week 1) and maintenance (weeks 2–8). Results: Flush-
ing severity with ER niacin was greatest during week 1 and remained greater than
placebo for the study duration. During weeks 2–8, 40% of patients on ER niacin
vs. 8% of those on placebo had > 1 day⁄week with ‘moderate or greater’ GFSS.
Conclusions: In conclusion, the GFSS component of the FSQ was a sensitive and
responsive quantitative measure of ER niacin-induced ﬂushing that will aid in the
objective comparison of novel strategies intended to improve tolerability and
adherence to niacin, an agent proven to reduce cardiovascular risk.
What’s known
Niacin has favourable effects on the lipid proﬁle;
however, its use in clinical practice has been
hampered by bothersome side effects, primarily
ﬂushing. The lack of a quantitative tool to assess
ﬂushing symptoms has precluded the objective
evaluation of niacin-induced ﬂushing.
What’s new
This study describes the utility of the Flushing
Symptom Questionnaire
ª (FSQ), a quantitative tool
to assess patient-reported ﬂushing end-points. The
results show that the FSQ is a useful patient-
reported outcome measure to objectively assess
ﬂushing associated with extended-release niacin.
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Patient selection criteria
Male and female patients 18–70 years of age for
whom ER niacin treatment was appropriate were eligi-
ble to be randomised. Other inclusion criteria were
triglycerides (TG) £ 27.5 mmol⁄l, alanine amino-
transferase or aspartate aminotransferase (ALT or
AST) < 1.5 · upper limit of normal (ULN), creatine
phosphokinase (CK) < 2 · ULN, normal thyroid
stimulating hormone as assessed by the investigator
and based on the central laboratory reference range of
0.300–5.000 lIU⁄ml, haemoglobin A1C £ 8.5%, and
commitment to maintaining a hand-held electronic
diary (e-diary). Non-study lipid-lowering medication
was permitted provided that the dose was stable
during the study. Low-dose aspirin (81 mg) dosed in
the morning was allowed for cardiac prophylaxis.
Patients with confounders for ﬂushing (e.g. post-
menopausal women with a history of ﬂushing, niacin
use > 50 mg⁄day, or aspirin use > 81 mg) or prior
history of hypersensitivity or intolerance to niacin
were excluded from the study. Medications to ame-
liorate or prevent ﬂushing symptoms were not per-
mitted.
Study design
This was an 8-week, multicentre, randomised, double-
blind, placebo-controlled study to assess patient-
reported ER niacin-induced ﬂushing end-points
during the initiation (week 1) and maintenance (weeks
2–8) phases of ER niacin (given as NIASPAN ;
Abbott Laboratories, Abbott Park, IL) therapy. After
completing a 1-week placebo run-in period, eligible
patients were randomised in a 3:3:3:2ratio to one
of four treatment groups (Figure 1). Following ran-
domisation, all groups underwent a 1-week initiation
treatment phase of either ER niacin 1 g⁄day (i.e. with-
out any titration dose; groups 1, 2 and 3) or placebo
(group 4). Afterwards, group 1 was administered ER
niacin 1 g for weeks 2–4 and then advanced to ER
niacin 2 g (2 · 1 g ER niacin pills) for weeks 5–8
(N1⁄N1⁄N2). Group 2 was administered ER niacin
1 g for weeks 2–4 and then continued on ER niacin
1 g (+1 matching placebo tablet to maintain blinding)
for weeks 5–8 (N1⁄N1⁄N1). Group 3 was switched
to matching placebo for weeks 2–4, with a second
placebo tablet to maintain blinding added for weeks
5–8 (N1⁄P⁄P). Group 4 received placebo matching
ER niacin, one tablet for weeks 1–4 and two tablets for
weeks 5–8 (P⁄P⁄P). All study medication was
administered with the evening meal rather than at
bedtime to allow adequate time for ER niacin-
induced ﬂushing symptoms to occur during the
wakeful hours. A poststudy telephone visit was
performed 14 days after discontinuation or comple-
tion visit of the study to assess for serious adverse
experiences.
The frequency, severity and bother of ﬂushing
(including symptoms of skin redness, warmth, tin-
gling and⁄or itching), the duration of ﬂushing and
sleep disturbance because of ﬂushing were assessed
using the 11-question FSQ (Figure 2) provided via
a hand-held e-diary. The e-diary was completed
each morning, and the results were uploaded to a
central database; the responses reﬂected the ﬂushing
symptoms (redness, warmth, itching and tingling)
experienced during the previous 24 h. Item 3 of the
FSQ, termed the Global Flushing Severity Score
(GFSS), assessed ﬂushing severity of all four symp-
toms in aggregate. In a separate FSQ validation
analysis of data from the present study, the GFSS
was selected as the best measure of ﬂushing severity
for use as an end-point in clinical trials of niacin-
based therapy (10). This study reports the results of
the GFSS to assess ER niacin-induced ﬂushing in
the initiation and chronic maintenance phases of
treatment with ER niacin.
Figure 1 Study design. Patients were randomised to one of four treatment sequence groups, represented by the group
designations shown at the end of each sequence. The group designations represent the treatment received during the
Initiation, Maintenance I and Maintenance II Phases of the study respectively. N1 = extended-release niacin 1 g;
N2 = extended-release niacin 2 g; P = placebo
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study retention included close patient follow-up
(daily uploading of e-diary data, frequent clinic visits
and drug accountability), educational materials
informing patients about the characteristics of ER
niacin-induced ﬂushing, non-pharmacologic mea-
sures (that were allowed by the trial) to reduce the
discomfort of ER niacin-induced ﬂushing, and
patient instruction regarding the importance of
remaining in the trial through to completion to
ensure an optimal assessment of ﬂushing severity.
The study was conducted in accordance with the
guidelines on good clinical practice and with ethical
standards for human experimentation established by
the Declaration of Helsinki. Ethics Review Commit-
tee⁄Institutional Review Board approval was
obtained for each study site. Informed consent was
obtained from all patients before any study proce-
dure was performed.
Study end-points
The primary end-points of the study included:
(i) the maximum GFSS during the 1-week treatment
initiation phase as a measure of ﬂushing severity in
the subjects receiving ER niacin 1 g during week 1
(allocation groups N1⁄P⁄P, N1⁄N1⁄N1 and
N1⁄N1⁄N2 combined) compared with the placebo
group and (ii) the percentage of days with a GFSS of
moderate or greater (‡ 4) during weeks 2 through 8
as a measure of ﬂushing severity during maintenance
of therapy. Other study end-points included duration
of ﬂushing episodes and discontinuation because of
ﬂushing symptoms.
Safety assessments included the collection of adverse
experiences (AEs), physical examination and vital
signs. Laboratory safety measurements included blood
chemistry (including AST, ALT and CK performed at
all treatment visits), haematology and urinalysis.
Prespeciﬁed discontinuation criteria included: per-
sistent ‡ 3· the ULN increases in ALT or AST; per-
sistent ﬁve to 10-fold increases in CK with muscle
symptoms; chronic (> 2 weeks) treatment with sys-
temic corticosteroids; TG levels ‡ 55 mmol⁄lo n
repeat measure; positive pregnancy test; or any con-
dition that exposed the patient to signiﬁcant risk by
continuing in the trial or did not permit the patient
to adhere to the requirements of the protocol.
Statistical methods
All randomised patients who took at least one dose
of postrandomisation study drug were included in
the analyses. The GFSS was calculated based on all
available data within the respective time interval, and
there was no imputation of missing data. Flushing in
the initiation phase was assessed by the GFSS during
week 1 as the maximum GFSS score (and separately
average GFSS score) as a continuous variable and
analysed using an ANOVA model with factor for
treatment and the maximum GFSS categorised as
none⁄mild, moderate, severe or extreme. Between-
treatment comparison was made using the Cochran–
Mantel–Haenszel test.
Flushing during various time intervals (e.g. weeks
2–8, weeks 2–4 and weeks 6–8) in the maintenance
phase was assessed as the percentage of days with
moderate or greater GFSS (GFSS ‡ 4) during the
time interval as a continuous variable and analysed
using an ANOVA model with factor for treatment
and the average GFSS score (and separately maxi-
mum GFSS score) during the time interval and anal-
ysed using an ANOVA model with factor for
treatment. For the weeks 2–4 time interval, the two
treatment groups that received ER niacin 1 g during
the ﬁrst 4 weeks of treatment were pooled together;
for time intervals beyond the ﬁrst 4 weeks of treat-
ment, each of the four treatment groups was analy-
sed separately.
Duration of ﬂushing episodes (in minutes) was
derived as the median across each patient’s daily
report from all non-missing diary records within the
time interval of interest. The percentages of patients
who discontinued study medication because of cuta-
neous symptoms were summarised by treatment.
Descriptive statistics, e.g. mean or median, including
standard deviation, were provided for each treat-
ment.
Results
Demographics and baseline characteristics
The demographics and baseline characteristics were
generally similar across the treatment groups
(Table 1). The randomised patient population had a
mean age of 48.7 years, included more males than
females (62% male vs. 38% female), was predomi-
nantly Caucasian (80.6%), and had a mean body
mass index of 30.1 kg⁄m
2.
Initiation of treatment
During week 1, patients receiving 1 g of ER niacin
experienced signiﬁcantly greater ﬂushing compared
with patients receiving placebo (p < 0.001 for
between-group comparison for ER niacin 1 g vs. pla-
cebo; Table 2). The analysis of the maximum GFSS
categorised during week 1 as none⁄mild, moderate,
severe or extreme demonstrated statistically signiﬁ-
cant (p < 0.001) differences between the ER niacin
1 g and placebo groups (Figure 3).
The daily mean GFSS during the ﬁrst 7 days of
treatment was examined for the patients receiving ER
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Among patients receiving ER niacin 1 g, ﬂushing
severity was greatest during the ﬁrst 2 days on treat-
ment, with 49% and 43% of patients having GFSS ‡
4 on days 1 and 2, respectively. Among patients
receiving placebo, < 15% of patients had GFSS ‡ 4
on any of the ﬁrst 7 days. The duration of ﬂushing
(minutes⁄day) analysis demonstrated that the median
ﬂushing duration was 0 min⁄day in the placebo
group vs. 22.5 min⁄day in the ER niacin 1 g group.
Maintenance treatment period
Patients who started on ER niacin 1 g in week 1 and
who remained on ER niacin 1 g or 2 g thereafter
reported the greatest ﬂushing severity in the ﬁrst
week; their ﬂushing severity decreased in the second
week but remained relatively constant throughout
the remaining weeks (Table 3, Figure 5). During
weeks 2 through 8, approximately 40% (30 of 75) of
the patients on ER niacin (1 g and 2 g combined) vs.
8% (six of 75) of the patients on placebo had more
than 1 day per week with moderate or greater GFSS
(Table 3). A small increase in ﬂushing was observed
when patients were advanced from 1 g to 2 g of ER
niacin at week 5.
The weekly mean proportions of days with moder-
ate or greater GFSS (‡ 4) were examined across
treatment groups (Figure 5). In the N1⁄N1⁄
N1 group, the mean weekly percentage of days with
moderate or greater GFSS was 34.1% at week 1, and
about 17.7% at week 2 and beyond. A similar proﬁle
was observed in the N1⁄N1⁄N2 group, with some
increase in ﬂushing at week 5 when the dose was
advanced from 1 to 2 g.
The N1⁄P⁄P group had a higher percentage of
days with moderate or greater GFSS during week 1;
Table 1 Demographics and baseline characteristics
Demographic⁄baseline
parameter
Placebo
(n = 33)
ER niacin 1 g
ﬁ placebo
(n = 51)
ER niacin 1 g
(n = 45)
ER niacin 1 g
ﬁ ER niacin 2 g
(n = 46)
All patients
(n = 175)
Mean age in years (SD) 48.4 (12.7) 46.1 (12.4) 51.1 (11.7) 49.7 (10.7) 48.7 (11.9)
Gender
Number of women (%) 9 (27.3) 17 (33.3) 19 (42.2) 22 (47.8) 67 (38.3)
Number of men (%) 24 (72.7) 34 (66.7) 26 (57.8) 24 (52.2) 108 (61.7)
Race
White (%) 25 (75.8) 41 (80.4) 34 (75.6) 41 (89.1) 141 (80.6)
Black (%) 3 (9.1) 3 (5.9) 4 (8.9) 0 (0) 10 (5.7)
Hispanic (%) 5 (15.2) 6 (11.8) 7 (15.6) 5 (10.9) 23 (13.1)
Other (%) 0 (0) 1 (2.0) 0 (0) 0 (0) 1 (0.6)
Mean BMI (kg⁄m
2) (SD) 30.4 (5.8) 28.9 (5.1) 30.4 (6.3) 31.0 (7.7) 30.1 (6.3)
ER, extended-release; SD, standard deviation; BMI, body mass index.
Table 2 Maximum GFSS during week 1 by treatment
group
Treatment
group n
Maximum
GFSS
during
week 1
Between-group
difference relative to
placebo in maximum
GFSS during week 1
LS mean
(95% CI)
LS mean
(95% CI) p-value
P 31 1.1 (0.2, 2.1)
N1 141 5.8 (5.4, 6.3) 4.7 (3.7, 5.8) < 0.001
P, placebo; N1, extended-release niacin 1 g; GFSS, Global
Flushing Severity Score; LS, least squares.
Figure 3 Maximum Global Flushing Severity Score in ﬁrst
study week (Initiation Phase). p < 0.001, based on
Cochran–Mantel–Haenszel test
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those for the placebo arm. The placebo group had a
low percentage of days with moderate or greater
GFSS across the entire treatment period.
Discontinuation because of ﬂushing
Overall, 14⁄175 patients (8%) discontinued because
of ﬂushing, all of whom were exposed to ER niacin.
Most (11⁄14) discontinuations because of ﬂushing
occurred during the ﬁrst week of the treatment (ini-
tiation dose at 1 g). None of the patients on ER nia-
cin 1 g with maximum GFSS during week 1 in
categories none⁄mild or moderate discontinued the
study because of ﬂushing, while 15.9% and 22.5% of
the patients with maximum GFSS during week 1 in
categories severe and extreme, respectively, discontin-
ued from the study within the ﬁrst week of treatment
because of ﬂushing. After the ﬁrst week, three more
patients discontinued from the study because of
ﬂushing. Compliance with study drug (92%) and
e-diary completion (87%) for the entire treatment
period was high and not typical of ‘real-world’ expe-
rience with niacin therapy, presumably because this
study was designed and monitored to maintain opti-
mal compliance.
Safety and tolerability
Overall, the safety proﬁle was similar to that
described in the NIASPAN label, despite that dosing
was according to a new paradigm (1 g ﬁ 2 g over
5 weeks rather than a four-step, 500 mg increment
titration to 2 g⁄day over 13 weeks). There were no
drug-related serious AEs reported in this study and,
with the exception of the observed ﬂushing response
that was recorded as an outcomes measure, ER
niacin was well tolerated.
Two ER niacin-treated patients experienced
ALT ‡ 2· but < 3· ULN (both in the 1 g group). Of
the 175 patients who entered the active treatment
period, only one had a laboratory AE (an increase in
CK in the N1⁄P⁄P group). The elevation was deter-
mined by the investigator to be not drug related.
There was no signiﬁcant difference in the incidence
of fasting blood glucose (FBG) values > 6.6 mmol⁄l
(i.e. 20% greater than ULN) in the ER niacin-treated
vs. placebo groups. There was a greater proportion
of patients with FBG increases > 10% in the groups
taking only ER niacin 1 g (51.5%) or 2 g (39.1%)
than in the P⁄P⁄P group (30.3%) and N1⁄P⁄P
groups (34.0%). There were no cases of new onset of
Figure 4 Percentage of patients with ‘moderate or greater’ ﬂushing (Global Flushing Severity Score ‡ 4) by day in the ﬁrst
7 days of treatment
Table 3 Percentage of days with moderate or greater*
GFSS during weeks 2 through 8
Treatment
group n
Percentage of
days with
moderate or
greater GFSS
Between-group
difference relative to
placebo
LS mean
(95% CI)
LS mean
(95% CI)
p-
value
P⁄P⁄P 33 7.2 ()0.4, 14.8)
N1⁄P⁄P 42 3.3 ()3.4, 10.0) )3.9 ()14.1, 6.2) 0.444
N1⁄N1⁄N1 39 17.5 (10.6, 24.5) 10.3 (0.05, 20.6) 0.049
N1⁄N1⁄N2 36 22.7 (15.4, 29.9) 15.5 (5.0, 25.9) 0.004
*Percentage of days during the speciﬁed study week(s) for
which patients reported GFSS ‡ 4. P, placebo; N1, extended-
release niacin 1 g; N2, extended-release niacin 2 g; GFSS,
Global Flushing Severity Score; LS, least squares.
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during the course of the trial. Greater proportions of
patients had platelet count decreases > 10% with
increasing exposure to ER niacin: such increases were
observed in 18% of the N1⁄P⁄P group, 23% of the
N1⁄N1⁄N1 group and 45% of the N1⁄N1⁄N2 group
vs. 9% of the P⁄P⁄P group.
Flushing symptoms were collected as an outcomes
measure when recorded by patients in the e-diary
and as a safety end-point when deﬁned by the inves-
tigator as a spontaneously occurring AE. Flushing
was the most frequently reported drug-related AE,
observed only in the groups treated with ER niacin.
Although some patients in the placebo group
reported ﬂushing on their daily e-diaries, there were
no investigator-deﬁned AEs of ﬂushing in the pla-
cebo group. The incidence of the drug-related AE of
ﬂushing increased with advancement of ER niacin
dose.
Discussion
In the present study, all of the predeﬁned FSQ-based
ﬂushing end-points succeeded in differentiating ER
niacin-treated from placebo-treated patients both
during the initiation and maintenance phases of
therapy. The usual ER niacin titration schedule was
not employed; rather, a provocative ER niacin dosing
regimen was selected to elicit ﬂushing symptoms;
consequently, the results of this study with the 1 g,
2 g ER niacin dosing regimen are not intended to be
generalisable for informing the tolerability of
branded ER niacin according to the approved prod-
uct label (e.g. titration schedule consisting of 500 mg
increases per 4-week period) (6). However, the FSQ
adds value to the evaluation of the magnitude of the
ER niacin-induced ﬂushing signal from any niacin
formulation, regardless of manner of dosing.
The primary comparison in the initiation phase
(week 1) was the maximum ﬂushing severity with
ER niacin vs. placebo. Flushing categorised as mod-
erate or greater was reported by 80% of patients tak-
ing ER niacin vs. 16% of patients taking placebo
during this week. The proportion of patients treated
with ER niacin who reported ﬂushing in this study
was consistent with that reported in other studies of
ER niacin. Among patients who received ER niacin,
the ﬂushing severity over week 1 was highest during
the ﬁrst 2 days on treatment. In contrast, fewer than
25% of patients who received placebo during week 1
had any ﬂushing (GFSS ‡ 1).
The observed placebo ﬂushing response demon-
strates that effective blinding controls were in place
(i.e. patients were not able to identify that they were
in the placebo group). Indeed, an ER niacin run-in
period prior to separation of groups was employed
to mitigate the risk of confounding the analysis in
the maintenance phase by unblinding of placebo
patients during the initiation phase. Moreover, the
symptoms of ﬂushing are commonly experienced for
many reasons in addition to treatment with niacin,
including the placebo effect of participating in an ER
niacin-induced ﬂushing study, underscoring the
importance of a validated tool to objectively assess
ﬂushing. Nevertheless, patients in the placebo group
experienced a shorter median duration of ﬂushing
than those in the ER niacin group (median duration
0 min⁄day vs. 22.5 min⁄day, respectively), suggesting
that while the GFSS is the best measure of ﬂushing
severity, other questions in the FSQ are useful for
discriminating the quality of ﬂushing depending on
aetiology.
Figure 5 Percentage of days with Global Flushing Severity Score of moderate or greater, by treatment group and study
week (mean ± standard error)
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phase (percentage of days with moderate or greater
GFSS during weeks 2 through 8) was of particular
interest as scant data assessing chronic ER niacin-
induced ﬂushing exist because of poor persistence
with niacin therapy. There appears to be an inconsis-
tency between the relatively low discontinuation rates
reported in clinical trials of ER niacin and the poor
persistence with ER niacin observed in clinical
practice (7–9). The present study demonstrated that
although the ﬂushing signal was modestly attenuated
in the second week, the frequency of ﬂushing
remained constant through the remaining weeks;
ﬂushing severity and bother with ER niacin contin-
ued to be greater than that with placebo for the
duration of the study. Overall, 40% of patients tak-
ing ER niacin vs. 8% of patients taking placebo had
more than 1 day per week with moderate or greater
(GFSS ‡ 4) ﬂushing. These results are generally con-
sistent with the previously reported experience with
niacin therapy in patients with dyslipidaemia.
Overall, 8% of patients discontinued because of
ﬂushing, none of whom came from the placebo
group. Most discontinuations occurred within the
ﬁrst week of the study and there was a clear relation-
ship between ﬂushing severity or bother and the
decision to discontinue therapy. Future studies will
be required to link the magnitude and persistence of
ER niacin-induced ﬂushing with discontinuation
behaviour.
Compliance with study drug (92%) and e-diary
completion (87%) were high and not typical of real-
world experience with niacin therapy; this study was
designed and monitored to maintain optimal treat-
ment compliance. Overall, ER niacin was well toler-
ated (independent of ﬂushing), with no serious,
drug-related AEs observed in this 8-week study. As
the duration of this study is short, the observed lack
of tolerability issues with ER niacin is not evidence
of its long-term safety. The observed safety proﬁle in
the present study is consistent with that described in
the ER niacin label (6).
In summary, the FSQ and particularly, the GFSS is
a useful patient-reported outcome measure to objec-
tively assess ER niacin-induced ﬂushing. The use of
patient-reported measures to characterise ER niacin-
induced ﬂushing will assist in the development of
novel strategies for improving tolerability and patient
adherence to niacin, an agent proven to reduce car-
diovascular risk.
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